ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
13 announcements
Krebs Biochemicals and Industries Limited has issued a notice for its 34th Annual General Meeting scheduled for September 29, 2026. Key agenda items include the approval of financial statements and related party transactions.
Krebs Biochemicals & Industries Limited has submitted its 34th Annual Report for the financial year 2025-26. The report includes financial highlights, directors' report, and audited financial statements.
Krebs Biochemicals & Industries Ltd reported revenue from operations of ₹7 Cr (+27.3% YoY) and a net loss of ₹2.5 Cr for Q1 FY27.
Krebs Biochemicals & Industries has scheduled a board meeting for August 6, 2026. The board will consider and adopt the unaudited Q1 results for June 30, 2026.
Krebs Biochemicals and Industries Ltd filed its shareholding pattern for June 2026, detailing promoter, institutional and other holdings. 20,400 promoter shares are in court dispute and remain undematerialised.
Krebs Biochemicals approved a merger with Ipca Laboratories Limited. The amalgamation aims for operational synergies and business consolidation.
Krebs Biochemicals submitted its Annual Secretarial Compliance Report for the financial year ended March 2026. The report details governance compliance and historical penalties for board composition.
Krebs Biochemicals & Industries Ltd reported revenue from operations of ₹6.8 Cr (+11.5% YoY) and a net loss of ₹2.3 Cr for Q4 FY26.
Krebs Biochemicals reported audited financial results for the year ended March 31, 2026. The company posted a total income of ₹25.76 Crore for the fiscal year.
Krebs Biochemicals & Industries Limited has scheduled a Board Meeting for May 21, 2026. The board will consider and adopt the audited financial results for the quarter and year ended March 31, 2026. Consequently, the trading window for company insiders remains closed until 48 hours after the result declaration.
Krebs Biochemicals & Industries Limited clarified to NSE that there is no undisclosed material information or events affecting the company's stock price movement. The company confirmed it remains in compliance with SEBI listing regulations regarding regular disclosures.
Krebs Biochemicals & Industries Limited clarified to BSE that there is no undisclosed material information or event causing the recent significant movement in its security price. The company maintains that it remains in compliance with SEBI listing regulations regarding regular dissemination of information.
Krebs Biochemicals & Industries Limited submitted the RTA certificate under Regulation 74(5) of SEBI DP Regulations for the quarter ended March 31, 2026. The filing confirms compliance regarding the dematerialization and rematerialization of securities during the period.